Oncology

Discussion in 'Pfizer' started by Anonymous, Jan 15, 2011 at 2:16 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Is Oncology laying off or expanding? What is left to sell? Aromasin is dead, Sutent is dying, Torisel is stagnant and Crizotinib may never be approved. Axitinib won't generate much $. An expansion would only mean mega layoffs in the future.